MARKET

RDY

RDY

Dr Reddys Labs
NYSE
52.22
-0.07
-0.13%
After Hours: 52.22 0 0.00% 16:00 09/29 EDT
OPEN
52.81
PREV CLOSE
52.29
HIGH
52.92
LOW
52.16
VOLUME
390.92K
TURNOVER
0
52 WEEK HIGH
67.40
52 WEEK LOW
47.54
MARKET CAP
8.67B
P/E (TTM)
23.05
1D
5D
1M
3M
1Y
5Y
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $69
Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $68 to $69.
Benzinga · 09/12 10:48
--Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating
--Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating
MT Newswires · 09/12 08:48
Journey Medical Completes Over 50% Enrollment in Phase 3 Trials of Treatment for Papulopustular Rosacea
Journey Medical Completes Over 50% Enrollment in Phase 3 Trials of Treatment for Papulopustular Rosacea
MT Newswires · 08/30 11:02
Sanofi, GSK gains as Citi sees limited impact from Zantac claims
The American Depository Shares of Sanofi (NASDAQ:SNY) (<a href="https://seekingal...
Seekingalpha · 08/26 14:12
Dr. Reddy's Laboratories Ltd Gets Establishment Inspection Report For Srikakulam, Andhra Pradesh Facility
- Reuters
Benzinga · 08/25 11:54
Intercept, Dr. Reddy’s settle patent dispute over Oclaiva generics
U.S. biotech Intercept Pharmaceuticals (NASDAQ:ICPT) an...
Seekingalpha · 08/17 19:49
Intercept Settles Ocaliva Litigation With Reddy's Lab
Benzinga · 08/17 14:16
BRIEF-Eton Pharmaceuticals Says Court Ruled To Uphold Exela Pharma Science's Patents - Filing
BRIEF-Eton Pharmaceuticals Says Court Ruled To Uphold Exela Pharma Science's Patents - Filing
Reuters · 08/15 10:34
More
About RDY
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

Webull offers kinds of Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.